Recursion Pharmaceuticals Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Chris Gibson
Chief executive officer
US$8.6m
Total compensation
| CEO salary percentage | 6.5% |
| CEO tenure | 11yrs |
| CEO ownership | 2.5% |
| Management average tenure | 1.4yrs |
| Board average tenure | 10.2yrs |
Recent management updates
Recent updates
Recursion: No News Isn't Good News When It Comes To Vanilla Pipeline
Nov 20Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week
Nov 10
Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Share Price Could Signal Some Risk
Nov 08Recursion: AI Is Only As Good As The Data
Sep 11Recursion: Path Forward For REC-994 Remains Despite Mixed Response
Sep 04Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 12Recursion Pharmaceuticals: AI-Driven 'TechBio' With Upcoming Catalysts
Aug 01Recursion Pharmaceuticals: More Of A TechBio Industrializing Drug Discovery
Jun 24Recursion Pharmaceuticals: Catalysts Are Coming And Success Is A Must
Jun 14Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%
May 22Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 12Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate
Apr 10Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade)
Mar 20Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely
Jan 31Recursion Pharmaceuticals: More Hype Than Substance Amid Signs Of Progress
Jan 12Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues
Dec 09What You Need To Know About The Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analyst Downgrade Today
May 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$378m |
| Jun 30 2024 | n/a | n/a | -US$375m |
| Mar 31 2024 | n/a | n/a | -US$354m |
| Dec 31 2023 | US$9m | US$561k | -US$328m |
| Sep 30 2023 | n/a | n/a | -US$293m |
| Jun 30 2023 | n/a | n/a | -US$260m |
| Mar 31 2023 | n/a | n/a | -US$249m |
| Dec 31 2022 | US$6m | US$498k | -US$239m |
| Sep 30 2022 | n/a | n/a | -US$247m |
| Jun 30 2022 | n/a | n/a | -US$234m |
| Mar 31 2022 | n/a | n/a | -US$212m |
| Dec 31 2021 | US$674k | US$485k | -US$186m |
| Sep 30 2021 | n/a | n/a | -US$147m |
| Jun 30 2021 | n/a | n/a | -US$124m |
| Mar 31 2021 | n/a | n/a | -US$99m |
| Dec 31 2020 | US$3m | US$270k | -US$87m |
Compensation vs Market: Chris's total compensation ($USD8.61M) is above average for companies of similar size in the US market ($USD5.37M).
Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.
CEO
Chris Gibson (41 yo)
11yrs
Tenure
US$8,613,208
Compensation
Dr. Christopher C. Gibson, Ph.D. also known as Chris, is Director of Cellino Biotech, Inc. from October 2024. Dr. Gibson is a Co-Founder of Recursion Pharmaceuticals Inc and serves as its Chief Executive O...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 11yrs | US$8.61m | 2.5% $ 41.2m | |
| Co-Founder & Director | 11.8yrs | US$292.74k | 2.46% $ 40.6m | |
| Chief Medical Officer | 1.4yrs | US$4.53m | 0.019% $ 309.7k | |
| CFO & President of Recursion UK | no data | no data | no data | |
| Chief Operating Officer | no data | no data | no data | |
| Vice President of Finance & Accounting | no data | no data | no data | |
| Chief Technology Officer | 4.8yrs | no data | no data | |
| Chief Scientific Officer | no data | no data | no data | |
| Senior Director of Investor Relations | 2.5yrs | no data | no data | |
| Chief Legal Officer & General Counsel | 1.1yrs | no data | no data | |
| Chief Communications Officer | 2.5yrs | no data | no data | |
| Chief People and Impact Officer | no data | no data | no data |
1.4yrs
Average Tenure
44.5yo
Average Age
Experienced Management: RXRX's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 11yrs | US$8.61m | 2.5% $ 41.2m | |
| Co-Founder & Director | 11.8yrs | US$292.74k | 2.46% $ 40.6m | |
| Chief R&D Officer | less than a year | no data | no data | |
| Member of Business Advisory Panel | 10yrs | no data | no data | |
| Member of Business Advisory Panel | 10.4yrs | no data | no data | |
| Chairman of Therapeutics Advisory Board | 3.3yrs | no data | no data | |
| Independent Chairman | 4.7yrs | US$302.74k | 0.013% $ 222.0k | |
| Co-Founder & Independent Director | 11yrs | US$300.25k | 1.11% $ 18.3m | |
| Independent Director | 6.3yrs | US$21.25k | 0.0033% $ 53.9k | |
| Member of Scientific and Technical Advisory Board | 10.6yrs | no data | no data | |
| Member of Scientific & Technical Advisory Board | 10.6yrs | no data | no data | |
| Independent Director | 8.2yrs | US$307.74k | 0.032% $ 535.5k |
10.2yrs
Average Tenure
61yo
Average Age
Experienced Board: RXRX's board of directors are seasoned and experienced ( 10.2 years average tenure).